Posted by Michael Wonder on 12 Nov 2021
Progress update: post-market review of medicines for smoking cessation
12 November 2021 - In June 2021, the Drug Utilisation Sub-Committee and the Economics Sub-Committee of the PBAC considered the report for the post-market review of medicines for smoking cessation.
The ESC requested that cost-effectiveness evaluations of combination therapies be conducted, as proposed in the review options. The Department has contracted an external evaluation group to conduct a cost effectiveness review of combinations of smoking cessation medicines.
